» Articles » PMID: 19158408

The Pathophysiology of Hypertension in Systemic Lupus Erythematosus

Overview
Specialty Physiology
Date 2009 Jan 23
PMID 19158408
Citations 39
Authors
Affiliations
Soon will be listed here.
Abstract

Systemic lupus erythematosus (SLE) is a chronic autoimmune inflammatory disorder that predominantly affects women during their reproductive years. Although SLE can affect any organ system, the kidneys are prominently involved in the form of immune complex glomerulonephritis. In addition, in women with SLE, risk for the development of cardiovascular disease is dramatically increased. Hypertension is a major risk factor for cardiovascular disease and is highly prevalent in women with SLE. Nevertheless, there has been little exploration of the pathophysiological mechanisms that promote SLE hypertension. This review discusses the role of several mechanisms, with an emphasis on the kidney, in SLE hypertension. These mechanisms include the renin-angiotensin system, endothelin, oxidative stress, sex steroids, metabolic changes, peroxisome proliferator-activated receptor-gamma, and, perhaps most importantly, chronic inflammation and cytokines. Growing evidence suggests a link between chronic inflammation and hypertension. Therefore, elucidation of mechanisms that promote SLE hypertension may be of significant value not only for patients with SLE, but also for a better understanding of the basis for essential hypertension.

Citing Articles

A case of posterior and reversible encephalopathy syndrome in a patient previously undiagnosed with lupus nephritis.

Kadoh Y, Yoshino J, Oka T, Itoga K, Hanada M, Niino D CEN Case Rep. 2025; .

PMID: 39918729 DOI: 10.1007/s13730-025-00973-8.


Comparison of Metabolic Syndrome, Autoimmune and Viral Distinctive Inflammatory Related Conditions as Affected by Body Mass Index.

Chero-Sandoval L, Martinez-Urbistondo M, Cuevas-Sierra A, Higuera-Gomez A, Martin-Domenech E, Castejon R J Clin Med. 2024; 13(21).

PMID: 39518437 PMC: 11547109. DOI: 10.3390/jcm13216298.


Immune Mechanisms in Hypertension.

Harrison D, Patrick D Hypertension. 2024; 81(8):1659-1674.

PMID: 38881474 PMC: 11254551. DOI: 10.1161/HYPERTENSIONAHA.124.21355.


Metabolic Modulators in Cardiovascular Complications of Systemic Lupus Erythematosus.

Minano S, Gonzalez-Correa C, Moleon J, Duarte J Biomedicines. 2023; 11(12).

PMID: 38137363 PMC: 10741086. DOI: 10.3390/biomedicines11123142.


Targeted stimulation of the vagus nerve reduces renal injury in female mice with systemic lupus erythematosus.

Shimoura C, Stubbs C, Chaudhari S, Dinh V, Mathis K Auton Neurosci. 2023; 250:103129.

PMID: 37950930 PMC: 11259125. DOI: 10.1016/j.autneu.2023.103129.


References
1.
Wilcox C . Oxidative stress and nitric oxide deficiency in the kidney: a critical link to hypertension?. Am J Physiol Regul Integr Comp Physiol. 2005; 289(4):R913-35. DOI: 10.1152/ajpregu.00250.2005. View

2.
Leibovitz E, Schiffrin E . PPAR activation: a new target for the treatment of hypertension. J Cardiovasc Pharmacol. 2007; 50(2):120-5. DOI: 10.1097/FJC.0b013e318062153b. View

3.
Bergamo P, Luongo D, Maurano F, Mazzarella G, Stefanile R, Rossi M . Conjugated linoleic acid enhances glutathione synthesis and attenuates pathological signs in MRL/MpJ-Fas(lpr) mice. J Lipid Res. 2006; 47(11):2382-91. DOI: 10.1194/jlr.M600187-JLR200. View

4.
Lebovitz H . The relationship of obesity to the metabolic syndrome. Int J Clin Pract Suppl. 2003; (134):18-27. View

5.
Rumi M, Ishihara S, Kazumori H, Kadowaki Y, Kinoshita Y . Can PPAR gamma ligands be used in cancer therapy?. Curr Med Chem Anticancer Agents. 2004; 4(6):465-77. DOI: 10.2174/1568011043352678. View